Analysis

Tscan Therapeutics, Inc. (TCRX) Stock Analysis

Tscan Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to TCRX.

websiteTCRX/analysis/TCRX

Tscan Therapeutics, Inc.

Tscan Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to TCRX.

Stock profile

Ticker

TCRX

Asset type

Stock

Market cap

$60.1M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Tscan Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • TCRX primary listing

Latest Tscan Therapeutics, Inc. news

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor ...

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor ...

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting and Exposition Announced

Research sections

Valuation

Review valuation context for Tscan Therapeutics, Inc..

Future growth

Review future growth context for Tscan Therapeutics, Inc..

Past performance

Review past performance context for Tscan Therapeutics, Inc..

Financial health

Review financial health context for Tscan Therapeutics, Inc..

Dividend

Review dividend context for Tscan Therapeutics, Inc..

Management

Review management context for Tscan Therapeutics, Inc..

Ownership

Review ownership context for Tscan Therapeutics, Inc..

Other information

Review other information context for Tscan Therapeutics, Inc..

Community

Review community context for Tscan Therapeutics, Inc..